Morbidity and Mortality Weekly Report: MMWR, Volume 33U.S. Department of Health, Education, and Welfare, Public Health Service, Center for Disease Control, 1983 |
From inside the book
Results 1-5 of 100
Page 371
... MOUNTAIN 325 357 5 269 319 Mont 2 5 13 34 Idaho 14 6 15 14 Wyo . 3 7 7 Colo 72 79 25 33 N Mex 44 111 54 61 Ariz 128 84 128 132 Utah 10 11 18 23 Nev . 52 54 16 15 0233 41227 92 543 12 60 1 23 60 65 6 19 395 10 3 109 1 57 33 18 9 21 ...
... MOUNTAIN 325 357 5 269 319 Mont 2 5 13 34 Idaho 14 6 15 14 Wyo . 3 7 7 Colo 72 79 25 33 N Mex 44 111 54 61 Ariz 128 84 128 132 Utah 10 11 18 23 Nev . 52 54 16 15 0233 41227 92 543 12 60 1 23 60 65 6 19 395 10 3 109 1 57 33 18 9 21 ...
Page 372
... MOUNTAIN 649 395 165 Akron , Ohio 85 52 17 5 4 7 - Albuquerque , N.Mex . 84 53 14 Canton , Ohio 23 19 2 2 Chicago , Ill 515 299 Cincinnati , Ohio 146 88 Cleveland , Ohio 172 102 Columbus , Ohio 140 81 821 Dayton , Ohio 81 52 Detroit ...
... MOUNTAIN 649 395 165 Akron , Ohio 85 52 17 5 4 7 - Albuquerque , N.Mex . 84 53 14 Canton , Ohio 23 19 2 2 Chicago , Ill 515 299 Cincinnati , Ohio 146 88 Cleveland , Ohio 172 102 Columbus , Ohio 140 81 821 Dayton , Ohio 81 52 Detroit ...
Page 383
... MOUNTAIN 26 12 16 6 13.144 13,880 33 16 Mont 1 563 608 Idaho 648 615 Wyo 1 389 365 2 Colo . 15 3,808 3,969 12 5 N. Mex . 1,479 1,654 2 Ariz 6 1 3,527 3,832 4 © 5 Utah 1 3 Nev . 3 1 643 2,087 686 13 1 2,151 1 PACIFIC 498 40 92 7 58,771 ...
... MOUNTAIN 26 12 16 6 13.144 13,880 33 16 Mont 1 563 608 Idaho 648 615 Wyo 1 389 365 2 Colo . 15 3,808 3,969 12 5 N. Mex . 1,479 1,654 2 Ariz 6 1 3,527 3,832 4 © 5 Utah 1 3 Nev . 3 1 643 2,087 686 13 1 2,151 1 PACIFIC 498 40 92 7 58,771 ...
Page 385
... MOUNTAIN 331 363 272 333 15 10 113 Mont 2 5 14 34 1 3 59 Idaho 14 6 15 17 Wyo . 3 7 8 Colo 75 80 25 33 5 N. Mex . 44 111 55 69 Ariz 131 88 129 134 Utah 10 12 18 23 2 Nev . 52 54 16 15 233 ' 61227 PACIFIC 2,250 2,803 8 Wash . 72 101 Oreg ...
... MOUNTAIN 331 363 272 333 15 10 113 Mont 2 5 14 34 1 3 59 Idaho 14 6 15 17 Wyo . 3 7 8 Colo 75 80 25 33 5 N. Mex . 44 111 55 69 Ariz 131 88 129 134 Utah 10 12 18 23 2 Nev . 52 54 16 15 233 ' 61227 PACIFIC 2,250 2,803 8 Wash . 72 101 Oreg ...
Page 386
... MOUNTAIN 595 362 137 · Albuquerque , N.Mex . 69 37 16 Colo . Springs , Colo . 33 25 Denver , Colo . 117 70 Las Vegas , Nev . 75 45 Ogden , Utah 21 10 Phoenix , Ariz . 135 76 Pueblo , Colo . 18 10 4 Salt Lake City , Utah 44 32 Tucson ...
... MOUNTAIN 595 362 137 · Albuquerque , N.Mex . 69 37 16 Colo . Springs , Colo . 33 25 Denver , Colo . 117 70 Las Vegas , Nev . 75 45 Ogden , Utah 21 10 Phoenix , Ariz . 135 76 Pueblo , Colo . 18 10 4 Salt Lake City , Utah 44 32 Tucson ...
Other editions - View all
Common terms and phrases
Acquired Immunodeficiency Syndrome age group Alaska animal antibody Ariz Calif cancer Centers for Disease City Civilian clinical Colo Congenital rubella syndrome Conn cryptosporidiosis death Department of Health Disease Control E.S. CENTRAL Editorial Note Encephalitis Epidemiologic exposure Gonorrhea Guam Hawaii hemophilia Hepatitis hospital human illness immunization Immunodeficiency Syndrome AIDS increased infants infection influenza isolates Kans Legionellosis Leptospirosis lowa Malaria Mass measles MID ATLANTIC Minn MMWR Mortality Weekly Report Mumps Nebr NIOSH occurred Ohio Okla Oreg outbreak Pa.t Pac Trust Terr PACIFIC patients persons Pertussis Poliomyelitis population Primary & Secondary Psittacosis Public Health rabies Reporting Area risk RMSF Rubella specified notifiable diseases surveillance symptoms Syphilis Tenn tick-borne Total Toxic Shock syndrome Trichinosis Tuberculosis Tularemia Typhus fever U.S. Government Printing Unavailable TABLE United Upstate Utah vaccine Viral virus Wash weeks ending WN CENTRAL
Popular passages
Page 11 - National Center for Health Statistics. NCHS growth curves for children birth- 18 years. United States. Rockville, MD: National Center for Health Statistics. 1977. (Vital and health statistics. Series 1 1: Data from the National Health Survey, no.
Page 397 - Corticosteroids, other immunosuppressive agents, and immunosuppressive illnesses can interfere with the development of active immunity and predispose the patient to developing rabies. Immunosuppressive agents should not be administered during postexposure therapy, unless essential for the treatment of other conditions. When rabies post-exposure prophylaxis is administered to persons receiving steroids or other immunosuppressive therapy, it is especially important that serum be tested for rabies antibody...
Page 633 - ... authority to convey the warnings to the vaccinee, parent, guardian, or other responsible person of the possibility of vaccine-associated paralysis, particularly to susceptible family members and other close personal contacts. The Centers for Disease Control report that during 1972 to 1983, approximately 278.8 million OPV doses were distributed in the United States. During this same period, 87 vaccine-associated cases in apparently immunologically normal individuals were reported. Thirty-two occurred...
Page 397 - Two cases of neurologic illness resembling Guillain-Barre syndrome*'* a transient neuroparalytic illness, that resolved without sequelae in 12 weeks and a focal subacute central nervous system disorder temporally associated with HDCV, have been reported.
Page 437 - In: Remington JS, Klein JO, eds. Infectious diseases of the fetus and newborn infant. Philadelphia: WB Saunders, 1983:636-678.
Page 597 - Human cryptosporidiosis in immunocompetent and immunodeficient persons: studies of an outbreak and experimental transmission.
Page 397 - Once initiated, rabies prophylaxis should not be interrupted or discontinued because of local or mild systemic adverse reactions to rabies vaccine. Usually such reactions can be successfully managed with anti-inflammatory and antipyretic agents (eg aspirin). Reactions after vaccination with HDCV are less common than with previously available vaccines.
Page 398 - ... Category C. Animal reproduction studies have not been conducted with IMOVAX RABIES Vaccine. It is also not known whether the product can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Rabies vaccine should be given to a pregnant woman only if clearly needed. Because of the potential consequences of inadequately treated rabies exposure and limited data that indicate that fetal abnormalities have not been associated with rabies vaccination, pregnancy...
Page 557 - Hypertension detection and follow-up program cooperative group. Fiveyear findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension.
Page 392 - ... bite a person should be captured and observed for symptoms of rabies for 10 days. If symptoms do not develop, the animal may be assumed to be non-rabid. If the animal dies or is killed, its head, undamaged, should be sent promptly, under refrigeration but not frozen, to a public health laboratory. Any wild animal that bites or scratches a person should be killed at once and the head kept under refrigeration during transportation to a public health laboratory. Rubber gloves should be worn by the...